Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>Magnetic resonance‐guided radiation therapy (MRgRT) has shown great promise for localization and real‐time tumor monitoring. However, to date, quantitative imaging has been limited for low field MRgRT. This work benchmarks quantitative T1, R2* and Proton Density (PD)‐mapping in phantom on a 0.35T MR‐linac and implements a novel acquisition method, <b>ST </b>rategically <b>A </b>cquired <b>G </b>radient <b>E </b>cho (STAGE). To further validate STAGE in a clinical setting, a pilot study was undertaken in a cohort of brain tumor patients to elucidate opportunities for longitudinal functional imaging with an MR‐linac in the brain. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>STAGE (two triple‐echo gradient echo (GRE) acquisitions) was optimized for a 0.35T low‐field MR‐linac. Simulations were performed to choose two flip angles to optimize signal‐to‐noise ratio (SNR) and T1‐mapping precision. Tradeoffs between SNR, scan time, and spatial resolution for whole‐brain coverage were evaluated in healthy volunteers. Data were inputted into a STAGE processing pipeline to yield 4 qualitative images (T1‐weighted, enhanced T1‐weighted, proton‐density (PD) weighted, and simulated FLuid‐Attenuated Inversion Recovery (sFLAIR)), and 3 quantitative datasets (T1, PD, and R2*). A benchmarking ISMRM/NIST phantom consisting of vials with variable NiCl<sub>2</sub> and MnCl<sub>2</sub> concentrations was scanned using variable flip angles (VFA) (2‐60 degrees) and inversion recovery (IR) methods at 0.35T. STAGE and VFA T1 values of vials were compared to IR T1 values. As measures of agreement with reference values and repeatability, relative error (RE) and coefficient of variability (CV) were calculated, respectively, for quantitative MR values within the phantom vials (spheres). To demonstrate feasibility, longitudinal STAGE data (pre‐treatment, weekly, and ~2 months post‐treatment) were acquired in an IRB‐approved pilot study of brain tumor cases via the generation of temporal and differential quantitative MRI maps. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>In the phantom, RE of measured STAGE and VFA T1 relative to IR reference values were 7.0 ± 2.5% and 9.5 ± 2.2%, respectively. RE for the PD vials was 8.1%±6.8% and CV for phantom R2* measurements was 10.1% ± 9.9%. Simulations and volunteer experiments yielded final STAGE parameters of FA=50°/10°, 1x1x3 mm<sup>3</sup> resolution, TR=40ms, TE=5/20/34ms in 10 minutes (64 slices). In the pilot study of brain tumor patients, differential maps for R2* and T1 maps were sensitive to local tumor changes and appeared similar to 3T follow up MRI datasets. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Quantitative T1, R2*, and PD mapping are promising at 0.35T agreeing well with reference data. STAGE phantom data offer quantitative representations comparable to traditional methods in a fraction of the acquisition time. Initial feasibility of implementing STAGE at 0.35T in a patient brain tumor cohort suggests that detectable changes can be observed over time. With confirmation in a larger cohort, results may be implemented to identify areas of recurrence and facilitate adaptive radiation therapy.</p></section>

Relaxation Along a Fictitious Field, continuous wave T1rho, adiabatic T1rho and adiabatic T2rho imaging of human gliomas at 3T: A feasibility study

Brain T1ρ Mapping for Grading and IDH1 Gene Mutation Detection of Gliomas: a Preliminary Study

Nimg-71. T2 Relaxivity And Diffusion Tensor Metrics In The Prediction Of Progression-Free Survival In Non-Recurrent High Grade Glioma

Downfield Proton MRSI at 3 Tesla: A Pilot Study in Human Brain Tumors

Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study

A comparison of 7 Tesla MR spectroscopic imaging and 3 Tesla MR fingerprinting for tumor localization in glioma patients

Investigated diagnostic value of synthetic relaxometry, three-dimensional pseudo-continuous arterial spin labelling and diffusion-weighted imaging in the grading of glioma

Rapid multicontrast brain imaging on a 0.35T MR‐linac

3D Amide Proton Transfer-Weighted Imaging for Grading Glioma and Correlating IDH Mutation Status: Added Value to 3D Pseudocontinuous Arterial Spin Labelling Perfusion

Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T

Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study

Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression

Repeatability and Reproducibility of pseudo-Continuous Arterial Spin Labeling Measured Brain Perfusion in Healthy Volunteers and Glioblastoma Patients

Experimental evaluation of accelerated T1rho relaxation quantification in human liver using limited spin-lock times.

Comparison of MRI Sequences to Predict IDH Mutation Status in Gliomas Using Radiomics-Based Machine Learning

Optimization and validation of low-field MP2RAGE T1 mapping on 0.35T MR-Linac: Toward adaptive dose painting with hypoxia biomarkers

Multi-parametric hyperpolarized 13 C/ 1 H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomas

Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis

Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas

MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region